Intriguingly, vessel density and blood flow recovery were enhanced by over-expressing TRPC5 upon injection of an adeno-associated virus construct encoding for TRPC5 or by administrating riluzole, the first medication approved by the Food and Drug Administration to treat amyotrophic lateral sclerosis (Zhu et al., 2019). The gene discussed is TRPC5; the disease is amyotrophic lateral sclerosis.